ClinicalTrials.gg

Program

plecanatide

Also written as “Plecanatide”, “SP-304 0.3 mg” and “SP-304 1.0 mg”.

Its studies are mostly in Constipation · Irritable Bowel Syndrome · Bronchiolitis Obliterans Syndrome, led by 2 companies.

Furthest: phase 3, since Sep 6, 201113 company-led studies, 1 open or runningNext primary completion: Oct 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies121 open or runningphase 3since Sep 6, 2011Jan 12, 2010Oct 18, 2027phase 2 · NCT07723924
Shandong Luoxin Pharmaceutical Group Stock10 open or runningphase 3since Nov 4, 2021Nov 4, 2021none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 12, 2010First study: phase 2 study in ConstipationNew to Bausch Health CompaniesBausch Health Companies · NCT01053962 · 84 enrolled · United States
  2. Sep 6, 2011Phase 3 study in ConstipationBausch Health Companies · NCT01429987 · 951 enrolled · United States
  3. Nov 2, 2012Phase 2 study in Irritable Bowel Syndrome Characterized by ConstipationBausch Health Companies · NCT01722318 · 428 enrolled · United States
  4. Aug 7, 2013Phase 3 study in Bronchiolitis Obliterans SyndromeBausch Health Companies · NCT01919697 · 2,370 enrolled · United States, Canada
  5. Nov 5, 2013Phase 3 study in ConstipationBausch Health Companies · NCT01982240 · 1,394 enrolled · United States, Canada
  6. Apr 22, 2014Phase 3 study in ConstipationBausch Health Companies · NCT02122471 · 1,410 enrolled · United States
  7. Jan 20, 2015Phase 3 study in Irritable Bowel Syndrome Characterized by ConstipationBausch Health Companies · NCT02387359 · 1,054 enrolled · United States
  8. Jun 23, 2015Phase 3 study in Irritable Bowel Syndrome Characterized by ConstipationBausch Health Companies · NCT02493452 · 1,135 enrolled · United States
  9. Feb 29, 2016Phase 3 study in Irritable Bowel SyndromeBausch Health Companies · NCT02706483 · 2,272 enrolled · United States
  10. Apr 18, 2017Phase 2 study in Chronic Idiopathic ConstipationBausch Health Companies · NCT03120520 · 124 enrolled · United States
  11. Jul 12, 2018Phase 2 study in Irritable Bowel Syndrome With ConstipationBausch Health Companies · NCT03596905 · 218 enrolled · United States
  12. Nov 4, 2021Shandong Luoxin Pharmaceutical Group Stock's first study: phase 3 study in Functional ConstipationNew to Shandong Luoxin Pharmaceutical Group StockShandong Luoxin Pharmaceutical Group Stock · NCT05151328 · 648 enrolled · China
  13. Jul 20, 2026Phase 2 study in ConstipationBausch Health Companies · NCT07723924 · 180 enrolled · United States

Ahead

  1. Oct 18, 2027Primary completion: phase 2 study in ConstipationBausch Health Companies · NCT07723924

TargetBeta

GUCY2C →read by rule
“An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities”NCIt, by rule
“Heat-stable enterotoxin receptor agonist”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07723924Constipation · United States2Active, not recruitingBausch Health CompaniesOct 18, 2027180
NCT05151328Functional Constipation · China3CompletedShandong Luoxin Pharmaceutical Group StockOct 12, 2023648
NCT03596905Irritable Bowel Syndrome With Constipation · United States2CompletedBausch Health CompaniesNov 25, 2024218
NCT03120520Chronic Idiopathic Constipation · United States2CompletedBausch Health CompaniesSep 7, 2018124
NCT02706483Irritable Bowel Syndrome · United States3CompletedBausch Health CompaniesMay 20172,272
NCT02493452Irritable Bowel Syndrome Characterized by Constipation · United States3CompletedBausch Health CompaniesNov 20161,135
NCT02387359Irritable Bowel Syndrome Characterized by Constipation · United States3CompletedBausch Health CompaniesDec 20161,054
NCT02122471Constipation · United States3CompletedBausch Health CompaniesMay 20151,410
NCT01982240Constipation · United States, Canada3CompletedBausch Health CompaniesApr 20151,394
NCT01919697Bronchiolitis Obliterans Syndrome · United States, Canada3CompletedBausch Health CompaniesJan 20162,370
NCT01722318Irritable Bowel Syndrome Characterized by Constipation · United States2CompletedBausch Health CompaniesApr 2014428
NCT01429987Constipation · United States3CompletedBausch Health CompaniesDec 2012951
NCT01053962Constipation · United States2CompletedBausch Health CompaniesAug 201084

How it is read

Names in the registry

  • “Plecanatide”, 10 entries
  • “plecanatide”, 2 entries
  • “SP-304 0.3 mg”, 1 entry
  • “SP-304 1.0 mg”, 1 entry
  • “SP-304 3.0 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.